Silo Pharma IncNASDAQ:SILO
- LAST PRICE1.4500
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.3100/ 2
- Ask / Lots1.5900/ 6
- Open / Previous Close1.4900 / 1.4500
- Day Range
- 52 Week Range
- Volume24,982
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SILO |
|---|---|---|
| 10:04 ET | 500 | 1.49 |
| 10:13 ET | 352 | 1.4901 |
| 10:22 ET | 300 | 1.5 |
| 10:49 ET | 100 | 1.48 |
| 11:50 ET | 2171 | 1.45 |
| 11:52 ET | 200 | 1.44 |
| 12:03 ET | 3468 | 1.45 |
| 12:08 ET | 4099 | 1.445 |
| 12:21 ET | 300 | 1.47 |
| 12:42 ET | 350 | 1.4791 |
| 12:44 ET | 500 | 1.479 |
| 12:48 ET | 499 | 1.47 |
| 12:57 ET | 1000 | 1.4798 |
| 01:04 ET | 1000 | 1.47 |
| 01:27 ET | 104 | 1.46 |
| 01:36 ET | 300 | 1.47 |
| 02:03 ET | 2290 | 1.43 |
| 02:05 ET | 1000 | 1.45 |
| 02:18 ET | 100 | 1.46 |
| 02:27 ET | 1113 | 1.43 |
| 02:30 ET | 637 | 1.435 |
| 02:36 ET | 300 | 1.4385 |
| 03:35 ET | 200 | 1.4401 |
| 03:44 ET | 200 | 1.495 |
| 03:48 ET | 100 | 1.4495 |
| 03:50 ET | 177 | 1.44 |
| 03:51 ET | 100 | 1.45 |
Nov 21, 2023
Nov 8, 2023
Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD, from 8:11AM ET on Wednesday Nov 08, 2023 by Dow Jones
8:11AM ET on Wednesday Nov 08, 2023 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Silo Pharma Inc | 4.5M | -1.1x | --- |
Artelo Biosciences Inc | 4.6M | -0.4x | --- |
Virpax Pharmaceuticals Inc | 4.6M | -0.6x | --- |
Aptinyx Inc | 4.4M | -0.1x | --- |
Transcode Therapeutics Inc | 4.4M | 0.0x | --- |
Revelation Biosciences Inc | 4.8M | -2.0x | --- |
Company Information
Silo Pharma, Inc. is a developmental stage biopharmaceutical company. The Company is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as Post-traumatic stress disorder (PTSD), Alzheimer's disease, and other rare neurological disorders. It is engaged in acquiring and/or developing intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological disorders. It has entered into a sponsored research agreement with Columbia University, pursuant to which it has been granted an option to license certain patents and inventions relating to the treatment of Alzheimer’s disease and stress-induced affective disorders using Ketamine in combination with certain other compounds.
Contact Information
- Headquarters
- 560 Sylvan Ave, Suite 3160ENGLEWOOD CLIFFS, NJ, United States 07632
- Phone
- 718-400-9031
- Fax
- ---
Executives
- Chairman of the Board, President, Chief Executive Officer
- Eric Weisblum
- Chief Financial Officer
- Daniel Ryweck
- Independent Director
- Wayne Linsley
- Independent Director
- Kevin Munoz
- Independent Director
- Jeff Pavell
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.5M |
|---|---|
Revenue (TTM) | $72.1K |
Shares Outstanding | 3.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.25 |
EPS | $-1.34 |
Book Value | $3.27 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | 62.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -6,029.95% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
